

Travel Vaccines Market Report by Composition (Mono Vaccines, Combination Vaccines), Disease (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, and Others), and Region 2024-2032

Market Report | 2024-01-30 | 139 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$3999.00
- Five User Licence \$4999.00
- Enterprisewide License \$5999.00

Report description:

The global travel vaccines market size reached US\$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 9.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.6% during 2024-2032. The market is experiencing steady growth driven by the escalating demand for exotic and off-the-beaten-path travel experiences, government initiatives to provide free travel vaccinations to their citizens as part of public health programs, and changing disease patterns and emerging threats.

Travel Vaccines Market Analysis:

Market Growth and Size: The market is witnessing strong growth, which can be attributed to increasing international travel activities. In addition, the rising awareness among the masses about travel-related diseases is bolstering the market growth.

Technological Advancements: Innovations in vaccine development, such as the introduction of more convenient and effective formulations, is ensuring better protection for travelers.

Industry Applications: Travel vaccines are crucial for both leisure and business travelers, as they offer protection against various diseases.

Geographical Trends: North America leads the market, on account of its strong emphasis on health and safety during travel. However, Europe is emerging as a fast-growing market, driven by its diverse range of destinations and a large number of international travelers.

Competitive Landscape: Key players in the market are actively engaged in strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks, and enhancing existing efficacy of vaccines.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Challenges and Opportunities: While the market faces challenges, such as vaccine hesitancy and regulatory hurdles, it also encounters opportunities in expanding vaccine accessibility and tailored vaccine solutions for specific regions.

Future Outlook: The future of the travel vaccines market looks promising, with ongoing research and development (R&D) activities in vaccine production. Moreover, the adoption of digital health solutions for pre-travel consultations is expected to propel the growth of the market.

Travel Vaccines Market Trends: Rising international travel

The increasing international travel among the masses around the world is supporting the growth of the market. As globalization and accessibility to travel are growing, the risk of exposure to infectious diseases in various parts of the world is rising. Travelers are venturing to destinations with varying healthcare standards and disease prevalence, making vaccinations a crucial precaution. This trend is further bolstered by the growth of leisure travel, business travel, and international students studying abroad. Moreover, the desire for exotic and off-the-beaten-path travel experiences is leading individuals to explore regions with unique health risks, emphasizing the need for specialized vaccines. The growing awareness among individuals about health precautions while traveling is underscoring the importance of vaccines for international travelers, which is offering a favorable market outlook.

Government initiatives and regulations

Government initiatives and regulations play a pivotal role in driving the market. Many countries are recognizing the importance of safeguarding public health and preventing the spread of diseases through international travel. As a result, governing agencies of several countries are implementing stringent regulations and recommendations regarding travel vaccinations. These regulations often mandate certain vaccinations for travelers entering or exiting their borders, especially for destinations with known disease risks. The International Health Regulations (IHR) by the World Health Organization (WHO) require proof of yellow fever vaccination for travelers visiting certain countries. Additionally, some governments offer subsidized or free travel vaccinations to their citizens as part of public health programs. These regulations and initiatives not only create a legal requirement for travelers but also raise awareness about the necessity of travel vaccines, driving demand in the market.

Global disease outbreaks and pandemics

Global disease outbreaks and pandemics have a profound impact on driving the market. These events are encouraging travelers and governments, highlighting the potential health risks associated with international travel. In response to such outbreaks, there is an escalating demand for vaccines that can protect against specific infectious diseases prevalent in certain regions. Disease outbreaks and pandemics are leading to the development and distribution of vaccines to mitigate the spread of the virus and facilitate safe travel. Travelers are becoming more conscious about the need for vaccinations to protect themselves and others, leading to greater adoption of travel vaccines. Governments and international health organizations also emphasize the importance of vaccines as a key tool in preventing and controlling outbreaks, encouraging travelers to be vaccinated before embarking on their journeys.

Changing disease patterns and emerging threats

The dynamic nature of disease patterns and the emergence of new infectious threats are strengthening the growth of the market. Infectious diseases are not static, they evolve, mutate, and spread to new regions. This ever-changing landscape necessitates ongoing research and development (R&D) activities of vaccines to combat evolving pathogens. Diseases like Zika virus and Ebola are emerging as significant concerns for travelers in recent years, prompting the development of specific vaccines to address these threats. This awareness of changing disease patterns, along with the ease of accessing information, is encouraging individuals to seek protection through vaccinations before embarking on their journeys.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Travel Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on composition and disease.

Breakup by Composition:

Mono Vaccines

Combination Vaccines

Combination vaccines account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the composition. This includes mono vaccines and combination vaccines. According to the report, combination vaccines represented the largest segment.

Combination vaccines offer the convenience of protecting against multiple diseases with a single injection. Popular combination vaccines include those that guard against hepatitis A and B, as well as typhoid. The primary advantage of combination vaccines is their efficiency in providing comprehensive protection, simplifying the vaccination process for travelers. This convenience is especially appealing to individuals who plan to visit regions with multiple disease risks, reducing the number of shots required. The combination vaccines segment is growing due to increased demand for streamlined vaccination regimens and improved compliance among travelers seeking a one-shot solution for their health needs.

Mono vaccines consist of individual vaccines targeting specific diseases. These vaccines are designed to provide protection against a single infectious agent, such as hepatitis A, hepatitis B, or typhoid. Mono vaccines are often recommended when travelers are visiting regions with a particularly high risk of one specific disease. They offer the advantage of targeted protection, allowing travelers to customize their vaccination regimen based on their destination and individual health needs.

Breakup by Disease:

Hepatitis A

DPT

Yellow Fever

Typhoid

Hepatitis B

Measles and Mumps

Rabies

Meningococcal

Varicella

Japanese Encephalitis

Others

Hepatitis A represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the disease. This includes hepatitis A, DPT, yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, varicella, Japanese encephalitis, and others. According to the report, hepatitis A represented the largest segment.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Hepatitis A is a highly contagious viral infection that can be contracted through contaminated food or water, making it a significant concern for travelers. This segment includes vaccines that provide immunity against the hepatitis A virus. Due to its prevalence in many travel destinations, hepatitis A vaccination is recommended for individuals traveling to regions with inadequate sanitation and hygiene standards. The prominence of hepatitis A in the market reflects the widespread recognition of its risk and the importance of vaccination for the health and safety of travelers.

DPT vaccines, which protect against diphtheria, pertussis (whooping cough), and tetanus, are another important segment in the travel vaccines market. While these diseases are not exclusive to travel-related risks, they are included in some international vaccination recommendations. Tetanus can be a concern if travelers are exposed to contaminated wounds during their journeys. Therefore, DPT vaccines are essential for ensuring comprehensive protection against these preventable diseases, even when traveling.

Yellow fever vaccines target the prevention of yellow fever, a mosquito-borne viral disease prevalent in certain tropical regions. Travelers visiting countries in Africa and South America where yellow fever is endemic often require proof of vaccination for entry. The yellow fever segment in the travel vaccines market serves travelers who plan to explore these high-risk areas and need to adhere to international health regulations.

Typhoid vaccines are essential for travelers heading to regions with a higher risk of typhoid fever, often linked to contaminated food and water sources. These vaccines protect against *Salmonella typhi*, the bacterium responsible for typhoid fever. The typhoid segment addresses the specific health needs of travelers venturing to areas with suboptimal sanitation and hygiene conditions.

Hepatitis B vaccines are important for travelers who may engage in activities that carry an elevated risk of exposure to the hepatitis B virus, such as unprotected sexual contact or medical procedures involving needles. While hepatitis B is not exclusive to travel, these vaccines cater to the needs of individuals seeking protection against this virus while away from their home country.

Breakup by Region:

- Asia Pacific
- North America
- Europe
- Middle East and Africa
- Latin America

North America leads the market, accounting for the largest travel vaccines market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share due to the high level of outbound international travel from the United States and Canada. The region has a strong emphasis on health and safety during travel, and travelers are well-informed about the importance of vaccinations. Additionally, government recommendations and regulations, including those set by the Centers for Disease Control and Prevention (CDC) in the United States, play a significant role in promoting the uptake of travel vaccines. North America also benefits from a well-established healthcare infrastructure and a robust pharmaceutical industry, making travel vaccines readily accessible to the population.

Europe is another substantial market for travel vaccines. With its diverse range of destinations and a large number of international travelers, European countries have a strong demand for travel vaccinations. The European Union is establishing guidelines for travelers, recommending vaccinations based on destination and health history. European travelers tend to be proactive in seeking

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

pre-travel healthcare advice, contributing to the growth of the market in the region.

The Asia Pacific region is experiencing rapid growth in the market due to a rise in outbound tourism and business travel. As economies in the region are expanding, more individuals have the means and desire to explore international destinations. This is resulting in a heightened awareness of travel-related health risks, catalyzing the demand for travel vaccines. Moreover, some countries are becoming popular tourist destinations, leading to an increase in inbound travelers who also require vaccinations.

The Middle East and Africa region also contribute to the market. This segment is driven by both outbound tourism and inbound travelers, as the region hosts various cultural, religious, and business events. Vaccinations are often mandated for individuals traveling to Mecca for Hajj or Umrah, further propelling the market growth. In addition, the presence of diseases like yellow fever and malaria underscores the importance of vaccinations for travelers.

Latin America is another growing market for travel vaccines, driven by increasing outbound travel from countries like Brazil and Mexico. Travelers from these regions often explore destinations within South America, North America, and Europe, necessitating vaccinations for disease prevention.

Leading Key Players in the Travel Vaccines Industry:

Key players in the market are actively engaged in several strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks and enhancing existing efficacy of vaccines. These companies are also focusing on increasing their global distribution networks to ensure accessibility to travel vaccines in diverse regions. Furthermore, they collaborate with healthcare providers, government agencies, and international health organizations to promote vaccination awareness and education among travelers. Additionally, pharmaceutical firms are exploring innovative vaccine delivery methods, such as oral or patch-based vaccines, to improve convenience and compliance for travelers. Overall, key players are dedicated to advancing the field of travel vaccines to meet the evolving needs of global travelers effectively.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

GlaxoSmithKline Pharmaceuticals Limited

Sanofi Pasteur

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

ALK-Abello A/S

Bavarian Nordic A/S

Crucell (Subsidiary of Johnson & Johnson)

CSL Limited

AstraZeneca PLC

Altimmune, Inc.

Abbott Laboratories

Hoffmann-La Roche, Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

March 31, 2021: Sanofi Pasteur announced a huge investment in a new vaccine manufacturing facility at its existing site in

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Toronto, Canada. The investment in a new facility will provide additional antigen and filling capacity for Sanofi's Fluzone® High-Dose Quadrivalent influenza vaccine, helping to increase supply availability in Canada, the United States and Europe.

January 5, 2022: Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

June 1, 2021: Merck & Co., Inc. announced that Vaxelis vaccine, developed as a part of a U.S. based partnership between Merck and Sanofi Pasteur is now available in the U.S. VAXELIS is the first and only hexavalent (six-in-one) combination vaccine available in the U.S. indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B.

Key Questions Answered in This Report

1. What is the size of the global travel vaccines market in 2023?
2. What is the expected growth rate of the global travel vaccines market during 2024-2032?
3. What are the key factors driving the global travel vaccines market?
4. What has been the impact of COVID-19 on the global travel vaccines market?
5. What is the breakup of the global travel vaccines market based on the composition?
6. What is the breakup of the global travel vaccines market based on the disease?
7. What are the key regions in the global travel vaccines market?
8. Who are the key companies/players in the global travel vaccines market?

Table of Contents:

- 1 Preface
- 2 Scope and Methodology
 - 2.1 Objectives of the Study
 - 2.2 Stakeholders
 - 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
 - 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
 - 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
 - 4.1 Overview
 - 4.2 Key Industry Trends
- 5 Global Travel Vaccines Market
 - 5.1 Market Overview
 - 5.2 Market Performance
 - 5.3 Impact of COVID-19
 - 5.4 Market Breakup by Composition
 - 5.5 Market Breakup by Disease
 - 5.6 Market Breakup by Region
 - 5.7 Market Forecast
- 6 Market Breakup by Composition
 - 6.1 Mono Vaccines
 - 6.1.1 Market Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.2 Market Forecast
- 6.2 Combination Vaccines
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 7 Market Breakup by Disease
 - 7.1 Hepatitis A
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
 - 7.2 DPT
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast
 - 7.3 Yellow Fever
 - 7.3.1 Market Trends
 - 7.3.2 Market Forecast
 - 7.4 Typhoid
 - 7.4.1 Market Trends
 - 7.4.2 Market Forecast
 - 7.5 Hepatitis B
 - 7.5.1 Market Trends
 - 7.5.2 Market Forecast
 - 7.6 Measles and Mumps
 - 7.6.1 Market Trends
 - 7.6.2 Market Forecast
 - 7.7 Rabies
 - 7.7.1 Market Trends
 - 7.7.2 Market Forecast
 - 7.8 Meningococcal
 - 7.8.1 Market Trends
 - 7.8.2 Market Forecast
 - 7.9 Varicella
 - 7.9.1 Market Trends
 - 7.9.2 Market Forecast
 - 7.10 Japanese Encephalitis
 - 7.10.1 Market Trends
 - 7.10.2 Market Forecast
 - 7.11 Others
 - 7.11.1 Market Trends
 - 7.12.2 Market Forecast
- 8 Market Breakup by Region
 - 8.1 North America
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
 - 8.2 Europe
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
 - 8.3 Asia Pacific
 - 8.3.1 Market Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.2 Market Forecast
- 8.4 Middle East and Africa
 - 8.4.1 Market Trends
 - 8.4.2 Market Forecast
- 8.5 Latin America
 - 8.5.1 Market Trends
 - 8.5.2 Market Forecast
- 9 Global Travel Vaccines Industry: SWOT Analysis
 - 9.1 Overview
 - 9.2 Strengths
 - 9.3 Weaknesses
 - 9.4 Opportunities
 - 9.5 Threats
- 10 Global Travel Vaccines Industry: Value Chain Analysis
 - 10.1 Exploratory Stage
 - 10.2 Preclinical and Clinical Development
 - 10.3 Regulatory Approval
 - 10.4 Manufacturing
 - 10.5 Marketing and Distribution
- 11 Global Travel Vaccines Industry: Porters Five Forces Analysis
 - 11.1 Overview
 - 11.2 Bargaining Power of Buyers
 - 11.3 Bargaining Power of Suppliers
 - 11.4 Degree of Competition
 - 11.5 Threat of New Entrants
 - 11.6 Threat of Substitutes
- 12 Global Travel Vaccines Industry: Price Analysis
- 13 Travel Vaccines Manufacturing Process
 - 13.1 Product Overview
 - 13.2 Raw Material Requirements
 - 13.3 Manufacturing Process
 - 13.4 Key Success and Risk Factors
- 14 Competitive Landscape
 - 14.1 Market Structure
 - 14.2 Key Players
 - 14.3 Profiles of Key Players
 - 14.3.1 GlaxoSmithKline Pharmaceuticals Limited
 - 14.3.2 Sanofi Pasteur
 - 14.3.3 Merck & Co., Inc.
 - 14.3.4 Novartis AG
 - 14.3.5 Pfizer Inc.
 - 14.3.6 ALK-Abello A/S
 - 14.3.7 Bavarian Nordic A/S
 - 14.3.8 Crucell (Subsidiary of Johnson & Johnson)
 - 14.3.9 CSL Limited
 - 14.3.10 AstraZeneca PLC
 - 14.3.11 Altimune, Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.3.12 Abbott Laboratories
14.3.13 Hoffmann-La Roche, Inc.

Travel Vaccines Market Report by Composition (Mono Vaccines, Combination Vaccines), Disease (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, and Others), and Region 2024-2032

Market Report | 2024-01-30 | 139 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Electronic (PDF) Single User	\$3999.00
	Five User Licence	\$4999.00
	Enterprisewide License	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-03-10

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com